International Stem Cell Corp (ISCO) 1.9700

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
International Stem Cell Corp (ISCO) 1.9700 $ISCO

International Stem Cell Corporation Announces Operating Results for the Three and Six-Months Ended June 30, 2016
GlobeNewswire - Tue Aug 16, 7:30AM CDT
International Stem Cell Corporation (OTCQB:ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and six months ended June 30, 2016.

International Stem Cell Corporation Announces Successful Cell Transplantation for the First Patient in Phase 1 Clinical Trial of ISC-hpNSC
GlobeNewswire - Thu Jul 28, 7:30AM CDT
International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, today announced that the first patient in the previously announced Phase I clinical trial has undergone a successful intracranial transplant of ISC-hpNSC as a treatment under investigation for Parkinson's Disease (PD). The operation took place at The Royal Melbourne Hospital in Australia.

International Stem Cell Corporation Announces Publication of Preclinical Results Demonstrating Treatment of Parkinson's Disease in Cell Transplantation
Marketwired - Thu Jun 02, 7:30AM CDT
CARLSBAD, CA--(Marketwired - June 02, 2016) - International Stem Cell Corporation (OTCQB: ISCO), a California-based clinical stage biotechnology company developing stem cell-based therapies and biomedical products, announced today that it has published the results of a 12-month pre-clinical, non-human primate study. The data demonstrates the safety and efficacy of the company's proprietary ISC-hpNSC® readily expandable neural stem cell derived treatment of Parkinson's disease.

Cryoport to Provide Cold Chain Logistics Support for International Stem Cell Corporation's Phase I Clinical Trial for the Treatment of Parkinson's Disease
PR Newswire - Mon May 23, 7:00AM CDT
Cryoport, Inc. (NASDAQ: CYRX) ("Company" , the world's leading cryogenic logistics company for the life sciences industry, today announced that it will provide global logistics support to International Stem Cell Corporation's (OTCQB: ISCO) ("ISCO" for its Phase I clinical trial in Australia for the treatment of moderate to severe Parkinson's disease. ISCO commenced patient enrollment for the study earlier this month.
CYRX: 2.10 (+0.10)

International Stem Cell Corporation Announces Operating Results for the Three-Months Ended March 31, 2016
Marketwired - Tue May 17, 7:31AM CDT
CARLSBAD, CA--(Marketwired - May 17, 2016) - International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three months ended March 31, 2016.

International Stem Cell Corporation Announces 2015 Fourth Quarter and Year-End Results
Marketwired - Thu Mar 31, 7:31AM CDT
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based clinical stage biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced fourth quarter and year-end financial results for the period ended December 31, 2015.

Retinitis Pigmentosa Pipeline Review, H2 2015 Featuring 27 Companies and Respective Drug Profiles
M2 - Fri Feb 05, 4:24AM CST
Research and Markets (http://www.researchandmarkets.com/research/pz5gtq/retinitis) has announced the addition of the "Retinitis Pigmentosa (Retinitis) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Retinitis Pigmentosa, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Retinitis Pigmentosa and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Retinitis Pigmentosa Overview - Therapeutics Development - Pipeline Products for Retinitis Pigmentosa - Overview - Pipeline Products for Retinitis Pigmentosa - Comparative Analysis - Retinitis Pigmentosa - Therapeutics under Development by Companies - Retinitis Pigmentosa - Therapeutics under Investigation by Universities/Institutes - Retinitis Pigmentosa - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Retinitis Pigmentosa - Products under Development by Companies - Retinitis Pigmentosa - Products under Investigation by Universities/Institutes - Retinitis Pigmentosa - Companies Involved in Therapeutics Development - Acucela Inc. - Amarantus Bioscience Holdings, Inc. - Applied Genetic Technologies Corporation - Asklepios BioPharmaceutical, Inc. - Caladrius Biosciences, Inc. - DNAVEC Corporation - Dompe Farmaceutici S.p.A. - Genable Technologies Limited - Genethon - GenSight Biologics SA - Grupo Ferrer Internacional, S.A. - InFlectis BioScience - International Stem Cell Corporation - Isis Pharmaceuticals, Inc. - Mimetogen Pharmaceuticals Inc. - Neurotech Pharmaceuticals, Inc. - Ocata Therapeutics, Inc. - Orphagen Pharmaceuticals, Inc. - QLT Inc. - RegenxBio Inc. - ReNeuron Group Plc - SanBio, Inc. - Sanofi - Shire Plc - Spark Therapeutics, Inc. - Sucampo Pharmaceuticals, Inc. - Sun Pharma Advanced Research Company Ltd. For more information visit http://www.researchandmarkets.com/research/pz5gtq/retinitis
OCAT: 8.47 (+0.01), QLTI: 1.42 (+0.01), ISIS: 57.56 (-0.28), ONCE: 58.35 (+1.10), SHPG: 200.63 (+0.81), SCMP: 11.49 (+0.18), GNST: (), CLBS: 5.42 (-0.03)

International Stem Cell Corporation Signed a Clinical Service Agreement With the Florey Institute of Neuroscience and Mental Health
Marketwire Canada - Wed Dec 23, 7:47AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) a clinical stage biotechnology company developing novel stem cell-based therapies, announced today that it has entered into a master clinical research agreement with the Florey Institute of Neuroscience and Mental Health (Florey) to conduct Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in Parkinson's disease (PD) patients. The Florey is one of the world's leading brain research centers, employing the largest neuroscience research team in Australia.

International Stem Cell Corporation Receives Authorization to Initiate Phase I/IIa Clinical Trial of ISC-hpNSC for the Treatment of Parkinson's Disease
Marketwired - Mon Dec 14, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a leader in using pluripotent stem cells in regenerative medicine, announced today that the Therapeutics Goods Administration (TGA) of Australia cleared a regulatory submission of ISCO's wholly owned subsidiary, Cyto Therapeutics, to initiate a Phase I/IIa clinical trial, dose escalation trial of human parthenogenetic stem cells-derived neural stem cells (ISC-hpNSC) in patients with moderate to severe Parkinson's disease (PD). Currently, there is no cure for PD, which is the second most common neurodegenerative disease and affects over 7 million people worldwide.

International Stem Cell Corporation Announces Launch Plans for New Nano-Compound Products
Marketwire Canada - Tue Dec 01, 7:30AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that its wholly-owned subsidiary Lifeline Skin Care, Inc. (Lifeline) will launch its next generation skin care product based on a breakthrough nano-compound technology in time for December holiday season.

International Stem Cell Corporation Announces Operating Results for the Three- and Nine-Months Ended September 30, 2015
Marketwired - Mon Nov 16, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO) (www.internationalstemcell.com) ("ISCO" or "the Company" , a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, today provided a business update and announced operating results for the three and nine months ended September 30, 2015.

International Stem Cell Corporation Moves Forward With Parkinson's Disease Clinical Trials in Australia
Marketwired - Tue Nov 03, 7:31AM CST
International Stem Cell Corporation (OTCQB: ISCO), a California-based biotechnology company developing novel stem cell-based therapies and biomedical products, announced today that after a recent meeting with Australian Therapeutics Goods Administration (TGA) the Company's wholly owned subsidiary Cyto Therapeutics signed a Letter of Intent (LOI) with Royal Melbourne Hospital (Australia) to conduct phase I/IIa clinical trials of ISCO's proprietary human parthenogenetic neural stem cells (hPNSCs) for the treatment of Parkinson's Disease. Under this process, a full agreement will be signed after TGA and the HREC approve the clinical protocol for the phase I/IIa trials.

U.S. Markets for Biologic and Tissue Engineered Devices 2015 - Cardiovascular and Neurological Products Analysis
M2 - Tue Oct 27, 9:41AM CDT
Research and Markets (http://www.researchandmarkets.com/research/fghmqn/u_s_markets_for) has announced the addition of the "U.S. Markets for Biologic and Tissue Engineered Devices - Cardiovascular and Neurological Products" report to their offering. Tissue engineering, or regenerative medicine, represents a promising therapeutic possibility for the treatment of aggressive and deadly diseases. Cellular therapies for cardiovascular disease (CVD) and neurological disease represent potential billion dollar markets that could offer a viable therapeutic option for a sizable patient population that has exhausted other therapeutic alternatives. Over 35 novel cellular therapies for cardiovascular and neurological disease are currently in development internationally, and in the United States (U.S.). The scope of the analysis of this report covers companies developing novel cellular therapeutics for the treatment of debilitating and deadly diseases that currently lack adequate therapeutic intervention. Cardiovascular disease-related conditions with cellular therapies in development are discussed in Chapter 2 of this report, which covers acute myocardial infarction, critical limb ischemia, heart failure, and bioengineered vascular grafts. Neurological conditions/diseases discussed in Chapter 3 of this report include Alzheimer's disease, ischemic stroke, Parkinson's disease, and spinal cord injury. Content included in this report includes: - Emerging cellular therapies for cardiovascular and neurological diseases - Companies and biotech firms developing novel cellular therapies - A prospective regulatory approval forecast for cellular therapy products currently in development for cardiovascular and neurological diseases - A speculative market analysis predicting the potential overall market values for cardiovascular and neurological disease stem cell therapies. Key Topics Covered: Executive Summary 1. Tissue Engineering and Cellular Therapy Tools and Techniques 1.1 Biomaterials 1.2 Cell Culture Technology 1.3 Stem Cell Technology 1.4 Immunoisolation Technology 2. Emerging Applications of Tissue Engineering and Cell Transplantation in Cardiovascular Disease Management 2.1 Cellular Therapy and Tissue Engineering 2.2 Cellular Therapy Administration 2.3 Clinical Experience with Stem Cell-Based Myocardial Tissue Repair and Regeneration 2.4 Cellular Therapies for Myocardial Repair and Regeneration in Development 2.5 Emerging Cellular Therapies for Limb Salvage in Critical Limb Ischemia Patients 2.6 Bioengineered Vascular Conduits 2.7 Current and Emerging U.S. Market for Cardiovascular Disease-Related Tissue Engineering and Cellular Therapy Products 3. Emerging Applications of Tissue Engineering and Cell Transplantation in Neurological Disease Management 3.1 Types of Cells Used for Cellular Therapies in Development 3.2 Emerging Stem Cell-Based Therapies for Alzheimer's Disease 3.3 Emerging Stem Cell-Based Therapies for Parkinson's Disease 3.4 Emerging Stem Cell-Based Therapies for Spinal Cord Injury 3.5 Emerging Stem Cell-Based Therapies for Post-Ischemic Stroke 3.6 Potential U.S. Market for Neurological Disease-Related Cellular Therapy Products Appendix: Company Listing Bibliography Companies Mentioned - Athersys - Baxter - Bioheart, Inc. - Biomet Biologics - Bukwang Pharmaceutical - Bundang CHA Hospital - Capricor Therapeutics - Chinese Academy of Military Medical Sciences - Cytori Therapeutics - Ecron Acunova - Fondazione IRCCS Ca'Granda, Ospedale Maggiore Policlinico - Harvest Technologies - Hospital Sao Rafael - Instituto de Medicina Regenerativa/Ageless Regenerative Institute - International Stem Cell Corporation - Medipost - Mesoblast Ltd. - NeoStem - Neuralstem - Neurogen Brain and Spine Insitute - Osiris Therapeutics - Pharmicell - Pluristem Therapeutics - ReNeuron, Ltd. - SanBio - StemCells, Inc. - Stemedica - Stempeutics - Taxus Cardium Pharmaceuticals Group - Terumo Corporation - The General Hospital of Chinese Armed Police Forces - Translational Biosciences - University of Irvine - Vericel For more information visit http://www.researchandmarkets.com/research/fg...arkets_for
CAPR: 3.60 (-0.06), PSTI: 1.67 (-0.06), CYTX: 2.19 (+0.03), OSIR: 5.20 (+0.02)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fapon's MEDICA 2026 Bid: Game-Changer or Same Old?

Updated Category News Views 37

Fapon's Ambitious Pitch at MEDICA: A Real Deal? MEDICA 2026 sees Fapon stepping up, laden with flashy promises and hardened expertise. Set up in Düsseldorf, these folks are pushing their Local Manufacturing Solutions harder than a door-to-door vacuum seller. The main pitch? Bolstering local IVD production with their comprehensive tech transfer services. How many outfits...

Continue Reading
HKEX Unveils New Offshore RMB Bond Index

Updated Category News Views 64

Here's the scoop: Hong Kong Exchanges and Clearing Limited (HKEX) just rolled out something worth eyeing—the HKEX Offshore RMB Bond Index. It's the first of its kind from HKEX, catered to those Dim Sum bonds floating around in the city. With Bloomberg lending a hand on the index smarts, this step is poised to give Hong Kong a leg up in the global financial marathon....

Continue Reading
Hanwha Power Seals Second FSRU Conversion Deal

Updated Category News Views 106

Riding the FSRU Wave with Hanwha Power Alright, we've got Hanwha Power step-dancing onto the LNG stage with its second splash into the FSRU (Floating Storage and Regasification Unit) conversion gig. Partnering up with Energos Infrastructure, these guys are making serious waves in the energy market by transforming what's pretty much a regular ship into a floating gas...

Continue Reading
D-Wave Quantum Hit with Securities Fraud Lawsuit

Updated Category News Views 380

A Legal Quagmire for D-Wave Quantum Investors Securities fraud lawsuits are like light in a dark alley—you need them when the truth's been stashed out of sight, but they illuminate the dirty and damp parts of investment strategies nobody wants to talk about. Right now, D-Wave Quantum Inc. is smack dab in the middle of such litigious action. If you had the misfortune of...

Continue Reading
Evotec’s $2.9M Grant Advances Drug Safety Tech

Updated Category News Views 63

Revitalizing Drug Development with Human Stem Cells Evotec's latest win—a crisp $2.9 million grant from the Gates Foundation—is like a shot of adrenaline for drug safety innovation. This isn't just another drop in the bucket; it's a solid boost toward improving how we screen potential drugs for fetal risks before they're tossed into the costly whirlpool of clinical...

Continue Reading
Sulzer Rebuilds Petrocedeño Tower: A Milestone in Oil Revival

Updated Category News Views 85

Venezuela's Oil Infrastructure Gets a Crucial Boost No one said reviving a near-busted oil facility in Venezuela would be a walk in the park. But that's just what North American Blue Energy Partners (NABEP) is doing, handing the reins to Sulzer to rebuild a busted crude tower at the Petrocedeño upgrader. This ain't just another run-of-the-mill repair job; this is the...

Continue Reading
Fortvita's Zybrivo Gains CHMP Nod: A European Leap

Updated Category News Views 23

It's not every day you're reading about a biotech making a ground-breaking shift off Chinese shores, but Fortvita's latest breakthrough is worth noting. Their fancy immunotherapy, Zybrivo® (sintilimab), just snagged a nod from the CHMP, Europe's committee that guides many on the medicinal merry-go-round. This isn't just your run-of-the-mill nod either. We're talking...

Continue Reading
Guangdong's APEC Trade: Deep Ties, Big Stakes

Updated Category News Views 160

A New Chapter in Guangdong's Economic Story Swing by the bustling streets of Shenzhen, and you'll catch more than a whiff of change in the air. With China gearing up to host the APEC Economic Leaders' Meeting for the third time, Guangdong is under the magnifying glass. But it's not just the international attention landing on the province that’s worth the chatter —...

Continue Reading
Segway Powersports Dominates Baja 1000 with Class 2 Sweep

Updated Category News Views 49

Catching the eye of any betting man, Segway Powersports has turned its maiden outing at the relentless SCORE Baja 1000 into a rousing victory. Their arrival on this unforgiving stage with a one-two in Class 2 isn't just a lucky roll—you don't chance upon podium sweeps in such gritty contests. Dissecting the Drive: Commitment and Coordination Unfolding across Baja's...

Continue Reading
Beef 'O' Brady's Expands Into Tuscaloosa Market

Updated Category News Views 348

A New Player in Town: Beef 'O' Brady's Lands in Tuscaloosa Listen up, sports fans and pub grub lovers of Tuscaloosa! Beef 'O' Brady's just kicked down the doors and expanded its reach, opening a location smack on McFarland Boulevard. The place threw open its doors on October 26 and is set to make waves in the local scene, driven by the dedicated hands of Mitul Patel and...

Continue Reading

Top 5 Most Recently Viewed Articles

Flow Beverage Welcomes José Bautista as Advisor and Announces Fundraising Progress

Updated Category News Views 336

Flow Beverage Corp. Welcomes José Bautista as Strategic Advisor Flow Beverage Corp. (TSX:FLOW; OTCQX:FLWBF) has recently made a significant move by bringing on board José Bautista as a Strategic Advisor. This addition is seen as a promising enhancement to the company's team, aligning with its dedication to excellence and innovation in the beverage sector. Background of...

Continue Reading
Milan Laser Hair Removal Marks a Significant 400 Clinic Milestone

Updated Category News Views 207

Milan Laser Hair Removal Reaches 400 Clinics Nationwide The leading provider in laser hair removal achieves a remarkable milestone with nationwide expansion efforts. Milan Laser Hair Removal, the hallmark of laser hair removal in the nation, proudly celebrates the grand opening of its 400th clinic, symbolizing a major advancement in its rapid expansion across the country....

Continue Reading
Global Vertical Roller Mill Market Expands to USD 1.04 Billion

Updated Category News Views 215

Understanding the Global Vertical Roller Mill Market The Vertical Roller Mill (VRM) market is anticipated to experience significant growth in the coming years. Currently valued at approximately USD 608.5 million in 2024, projections indicate that it will reach USD 1,041.2 million by 2033, achieving a compound annual growth rate (CAGR) of 6.1%. This increase is largely due...

Continue Reading
Pulsar Helium Provides Insights on Progress at Topaz Project

Updated Category News Views 313

Pulsar Helium Develops Well-Testing Strategy at Topaz Project Pulsar Helium Inc. (AIM: PLSR, TSXV: PLSR, OTCQB: PSRHF), a leading helium development company, has recently provided valuable updates regarding its well-testing activities at the Topaz project, located in Minnesota. This momentous phase in the project holistically aims to assess helium extraction capabilities...

Continue Reading
Trade Disclosures: Treatt plc's Key Operations Analyzed

Updated Category News Views 178

Understanding Recent Trade Disclosures by Treatt plc Treatt plc, a company known for its expertise in manufacturing and distributing essential oils and flavouring agents, operates in a competitive sector where trade disclosures play a crucial role in maintaining transparency and building investor trust. As we delve into the recent disclosures made by Treatt plc, we'll...

Continue Reading